MOST Study

Condition: Stroke

Eligibility

Key Inclusion Criteria

  • Acute ischemic stroke patients
  • Treated with 0.9 mg/kg IV rt-PA within 3 hours of stroke onset or time last known well
  • At least 18 years old

Key Exclusion Criteria

  • Known allergy or hypersensitivity to argatroban or eptifibatide
  • Previous stroke in the past 90 days
  • Previous intracranial hemorrhage, neoplasm, subarachnoid hemorrhage or arterial venous malformation

Full Study Name

Multi-Arm Optimization of Stroke Thrombolysis (MOST) Stroke Trial (IRB no. 55772)

Summary

This study focuses on patients who are having a stroke caused by a clot blocking blood flow to the brain and who are already being treated with the clot-busting medicine tPA (alteplase). Even with tPA treatment, the blood vessels sometimes block up again when tPA wears off, which can worsen the stroke. The purpose of the study is to determine whether adding one of two blood-thinning medicines (argatroban or eptifibatide) to standard treatment helps to keep blood vessels open, decrease the impact of strokes and is safe. Both drugs are approved by the U.S. Food and Drug Administration (FDA) as blood thinners, but they are not approved for treating strokes.

Participants will be randomly assigned to one of three groups (Group A, B, or C). All groups will receive standard treatment with tPA. In addition, Group A will receive a placebo (inactive substance) solution; Group B will receive argatroban; and Group C will receive eptifibatide.

Principal Investigator

Patrick Lyden, MD

Contact

Vicki Manoukian
Phone: 310-423-5067
vicki.manoukian@cshs.org